PT  - JOURNAL ARTICLE
AU  - Kurt Spiteri Cornish
AU  - Lucia Kuffova
AU  - John V Forrester
TI  - Treatment of diffuse subretinal fibrosis uveitis with rituximab
AID  - 10.1136/bjophthalmol-2013-304686
DP  - 2015 Feb 01
TA  - British Journal of Ophthalmology
PG  - 153--154
VI  - 99
IP  - 2
4099  - http://bjo.bmj.com/content/99/2/153.short
4100  - http://bjo.bmj.com/content/99/2/153.full
SO  - Br J Ophthalmol2015 Feb 01; 99
AB  - Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.